ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors

Current treatment for advanced stage ovarian clear cell cancer is severely hampered by a lack of effective systemic therapy options, leading to a poor outlook for these patients. Sequencing studies revealed that ARID1A is mutated in over 50% of ovarian clear cell carcinomas. To search for a rational...

Descripción completa

Detalles Bibliográficos
Autores principales: Berns, Katrien, Caumanns, Joseph J., Hijmans, E. Marielle, Gennissen, Annemiek M. C., Severson, Tesa M., Evers, Bastiaan, Wisman, G. Bea A., Jan Meersma, Gert, Lieftink, Cor, Beijersbergen, Roderick L., Itamochi, Hiroaki, van der Zee, Ate G. J., de Jong, Steven, Bernards, René
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6095834/
https://www.ncbi.nlm.nih.gov/pubmed/29760405
http://dx.doi.org/10.1038/s41388-018-0300-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6095834/
https://www.ncbi.nlm.nih.gov/pubmed/29760405
http://dx.doi.org/10.1038/s41388-018-0300-6

Ejemplares similares